Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pinometostat in Pediatric MLL-Rearranged Leukemias
NCT02141828Phase 1Completed
- Sponsor
- Epizyme, Inc.
- Start
- May 2014
- Primary completion
- May 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of pinometostat in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and acute leukemia, sponsored by Epizyme, Inc. Primary endpoints: Maximum Tolerated Dose at 12 months and Safety and Tolerability at 22 months. Started May 2014; status: completed.
02
Drugs
pinometostat
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia
Beyond the preview
Go deeper on NCT02141828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02141828.